Session Information
-
WCLC 2021
2022 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
GA01 - IASLC General Assembly
- 15:00 - 16:00
- 9/12/2021
- Location: Program Auditorium
- Type: Highlights
- Track: N.A.
-
+
GA01.01 - Welcome
15:00 - 15:00 | Presenter: Tetsuya Mitsudomi
- Abstract
No abstract available for this presentation
-
+
GA01.02 - Recognition of Outgoing & Incoming IASLC Board of Directors
15:00 - 15:00 | Presenter: Tetsuya Mitsudomi, Heather Wakelee
- Abstract
No abstract available for this presentation
-
+
GA01.03 - Scientific Activities Report
15:00 - 15:00 | Presenter: Giorgio Vittorio Scagliotti
- Abstract
No abstract available for this presentation
-
+
GA01.04 - Financial Report
15:00 - 15:00 | Presenter: John Skadow
- Abstract
No abstract available for this presentation
-
+
GA01.05 - IASLC State of the State
15:00 - 15:00 | Presenter: Kristin Richeimer (IASLC Interim CEO)
- Abstract
No abstract available for this presentation
-
+
GA01.06 - IASLC President Parting Comments
15:00 - 15:00 | Presenter: Tetsuya Mitsudomi
- Abstract
No abstract available for this presentation
-
+
GA01.07 - Wrap Up & Adjourn
15:00 - 15:00 | Presenter: Heather Wakelee
- Abstract
No abstract available for this presentation
-
+
MTE05 - Meet the Expert - Pharmaceutical/Biotech Industry
- 15:00 - 16:00
- 9/12/2021
- Location: IASLC Booth via Industry Hub and Exhibit Hall
- Not for CME Credit
- Type: Meet the Expert Sessions
- Track: N.A.
- Moderators:Melina E. Marmarelis
-
+
MTE05.01 - Pharmaceutical/Biotech Industry
15:00 - 16:00 | Presenter: Bob Marchesani
- Abstract
No abstract available for this presentation
-
+
MTE06 - Meet the Expert - Academic and Community Crossover - Increasing Interdisciplinary Collaboration
- 15:00 - 16:00
- 9/12/2021
- Location: IASLC Booth via Industry Hub and Exhibit Hall
- Not for CME Credit
- Type: Meet the Expert Sessions
- Track: N.A.
- Moderators:Sonam Puri
-
+
MTE06.01 - Academic and Community Crossover - Increasing Interdisciplinary Collaboration
15:00 - 16:00 | Presenter: Sarah B Goldberg
- Abstract
No abstract available for this presentation
-
+
PL03 - Plenary 3: Screening: The Global Landscape, Progress, and Future Directions (Japanese, Mandarin, Spanish Translation Available)
- 16:15 - 17:15
- 9/12/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
- Moderators:Karen Canfell, Ella Kazerooni
-
+
PL03.01 - Lung Cancer Screening in Europe: Current Status
16:15 - 16:27 | Presenter: Ugo Pastorino
- Abstract
No abstract available for this presentation
-
+
PL03.02 - Lung Cancer Screening in Latin America: Current Status and Challenges
16:27 - 16:39 | Presenter: Ricardo Santos
- Abstract
Loading... -
+
PL03.03 - Lung Cancer Screening in Asia
16:39 - 16:51 | Presenter: Li FAN
- Abstract
No abstract available for this presentation
-
+
PL03.04 - Radiomics in Lung Cancer Radiation Treatment Assessment: Recent Progress and Future Directions
16:51 - 17:03 | Presenter: Fang-Fang Yin
- Abstract
No abstract available for this presentation
-
+
PL03.05 - Live Discussion with Speakers
17:03 - 17:15
- Abstract
No abstract available for this presentation
-
+
MA09 - Predictive Markers for Immunotherapy
- 17:30 - 18:30
- 9/12/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
-
+
MA09.01 - LCMC3: Immune Cell Subtypes Predict Nodal Status and Pathologic Response After Neoadjuvant Atezolizumab in Resectable NSCLC
17:30 - 17:35 | Presenter: Filiz Oezkan
- Abstract
Loading... -
+
MA09.02 - SAKK 16/14 - T-Cell Receptor Repertoire Metrics Predict Response to Neoadjuvant Durvalumab in Patients With Stage IIIA(N2) NSCLC
17:35 - 17:40 | Presenter: Sacha I Rothschild
- Abstract
Loading... -
+
MA09.03 - Peripheral CD8+ T Cells Predicts Immune-Related Adverse Events and Survival in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy
17:40 - 17:45 | Presenter: Kan Wu
- Abstract
Loading... -
+
MA09.04 - Discussant
17:45 - 18:00 | Presenter: Benjamin Levy
- Abstract
No abstract available for this presentation
-
+
MA09.05 - PD1-Positive Tertiary Lymphoid Structure as a Predictive Factor of Durable Clinical Effect in Immunotherapy for NSCLC
18:00 - 18:05 | Presenter: Yuki Matsumura
- Abstract
Loading... -
+
MA09.06 - Mature Tertiary Lymphoid Structures in Lung Adenocarcinoma Are Associated With Better Progression Free Survival
18:05 - 18:10 | Presenter: Rebecca C Obeng
- Abstract
Loading... -
+
MA09.07 - Genomic Landscape and Clinical Outcomes With Immune Checkpoint Inhibitors in NF1-Mutant NSCLC
18:10 - 18:15 | Presenter: Marcelo Vailati Negrao
- Abstract
Loading... -
+
MA09.08 - Discussant
18:15 - 18:30 | Presenter: Sabina Berezowska
- Abstract
No abstract available for this presentation
-
+
MA10 - Screening and Early Detection: An Overview
- 17:30 - 18:30
- 9/12/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Screening and Early Detection
-
+
MA10.01 - Prospective Evaluation of the International Lung Screening Trial (ILST) Protocol for Management of First Screening LDCT
17:30 - 17:35 | Presenter: Renelle Myers
- Abstract
Loading... -
+
MA10.02 - Lung Cancer Detected By Screening, Incidental Lung Nodule Program and Neither: A Prospective Observational Study
17:35 - 17:40 | Presenter: Raymond Uyiosa Osarogiagbon
- Abstract
Loading... -
+
MA10.03 - Balance Between Decreased False Positives and Delayed Diagnosis in Lung Cancer Screening
17:40 - 17:45 | Presenter: Rowena Yip
- Abstract
Loading... -
+
MA10.04 - Discussant
17:45 - 18:00 | Presenter: Mary Pasquinelli
- Abstract
No abstract available for this presentation
-
+
MA10.05 - Potential of CT and PET-Based Radiomics for the Diagnosis of Lung Adenocarcinomas Indicated for Limited Resection
18:00 - 18:05 | Presenter: Nobuyuki Yoshiyasu
- Abstract
Loading... -
+
MA10.06 - Factors Associated with Lung Cancer Screening Adherence Among Patients with Negative Baseline Nodule Finding
18:05 - 18:10 | Presenter: Mehrad Bastani
- Abstract
Loading... -
+
MA10.08 - Discussant
18:15 - 18:30 | Presenter: Nir Peled
- Abstract
No abstract available for this presentation
-
+
OA13 - Topics of Pleural Mesothelioma
- 17:30 - 18:30
- 9/12/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Mesothelioma, Thymoma and Other Thoracic Malignancies
- Moderators:Raphael Bueno
-
+
OA13.01 - S1619 A Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and Maintenance for Resectable Pleural Mesothelioma
17:30 - 17:40 | Presenter: Anne Tsao
- Abstract
Loading... -
+
OA13.02 - Socioeconomic Disparities in Access to Treatment and Survival in Operable Malignant Pleural Mesothelioma in the United States
17:40 - 17:50 | Presenter: Estelamari Rodriguez
- Abstract
Loading... -
+
OA13.03 - Type M1 and Type M2 Macrophages Are Associated With Patient Survival in Malignant Pleural Mesothelioma
17:50 - 18:00 | Presenter: Hely Tytti Ollila
- Abstract
Loading... -
+
OA13.04 - Chromosomal Rearrangements and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors
18:00 - 18:10 | Presenter: Farhad Kosari
- Abstract
Loading... -
+
OA13.05 - Discussant
18:10 - 18:20 | Presenter: Harvey Pass
- Abstract
No abstract available for this presentation
-
+
OA13.06 - Live Discussion with Speakers
18:20 - 18:30
- Abstract
No abstract available for this presentation
-
+
MA11 - New Biological Insights for Targeted Therapies
- 18:45 - 19:45
- 9/12/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Tumor Biology and Systems Biology: Basic and Translational Science
-
+
MA11.01 - Development of Novel EGFR Mutant NSCLC Mouse Models and Murine Cell Lines: New Tools for NSCLC Research
18:45 - 18:50 | Presenter: Emily K Kleczko
- Abstract
Loading... -
+
MA11.02 - Targeting HER2 Exon 20–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor, Mobocertinib
18:50 - 18:55 | Presenter: Han Han
- Abstract
Loading... -
+
MA11.03 - Phase Separation Orchestrates EML4-ALK Signaling and Promotes Tumorigenesis
18:55 - 19:00 | Presenter: Zhen Qin
- Abstract
Loading... -
+
MA11.04 - Discussant
19:00 - 19:15 | Presenter: Katerina Politi
- Abstract
No abstract available for this presentation
-
+
MA11.05 - Lysyl Oxidase Inhibition Triggers Phenotypic Transition
19:15 - 19:20 | Presenter: YUEQING CHEN
- Abstract
Loading... -
+
MA11.06 - Multi-Omic Characterization of Lung Tumors Implicates AKT and MYC Signaling in Adenocarcinoma to Squamous Cell Transdifferentiation
19:20 - 19:25 | Presenter: Alvaro Quintanal-Villalonga
- Abstract
Loading... -
+
MA11.07 - Lung Squamous Cell Carcinoma Prognosis Based on Ferroptosis DNA Methylation Status
19:25 - 19:30 | Presenter: Xuequan Wang
- Abstract
Loading... -
+
MA11.08 - Discussant
19:30 - 19:45 | Presenter: Humam Kadara
- Abstract
No abstract available for this presentation
-
+
OA14 - Global Disparities in Lung Cancer Care
- 18:45 - 19:45
- 9/12/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Global Health
- Moderators:Luis Mas
-
+
OA14.01 - Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)
18:45 - 18:55 | Presenter: Virginia Calvo
- Abstract
Loading... -
+
OA14.02 - Social Vulnerability Is an Independent Risk Factor in Patients Undergoing Surgical Treatment of Lung Cancer
18:55 - 19:05 | Presenter: Ricardo Mingarini Terra
- Abstract
Loading... -
+
OA14.03 - Discussant
19:05 - 19:15 | Presenter: Nan Wu
- Abstract
No abstract available for this presentation
-
+
OA14.04 - Live Discussion with Speakers
19:15 - 19:45
- Abstract
No abstract available for this presentation
-
+
OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation
- 18:45 - 19:45
- 9/12/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Novel Therapeutics and Targeted Therapies
- Moderators:Helena A Yu
-
+
OA15.01 - Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
18:45 - 18:55 | Presenter: Alexander Spira
- Abstract
Loading... -
+
OA15.02 - Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations
18:55 - 19:05 | Presenter: Pasi A. Janne
- Abstract
Loading... -
+
OA15.03 - Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS
19:05 - 19:15 | Presenter: Alexander Spira
- Abstract
Loading... -
+
OA15.04 - Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer
19:15 - 19:25 | Presenter: D. Ross Camidge
- Abstract
Loading... -
+
OA15.05 - Discussant
19:25 - 19:35 | Presenter: Federico Cappuzzo
- Abstract
No abstract available for this presentation
-
+
OA15.06 - Live Discussion with Speakers
19:35 - 19:45
- Abstract
No abstract available for this presentation
